Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER vs AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CLINIMIX E 5/15 is a parenteral nutrition solution that provides essential amino acids, electrolytes, and dextrose for intravenous use. Amino acids serve as building blocks for protein synthesis, dextrose provides calories for energy metabolism, and electrolytes maintain fluid and electrolyte balance. Calcium is essential for bone mineralization, neuromuscular function, and enzyme activation.
Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.
Parenteral nutrition for patients who cannot obtain adequate nutrition orally or enterally,Provision of calories, amino acids, electrolytes, and calcium in patients with, or at risk of, fluid overload, hyperglycemia, or electrolyte imbalance
Treatment of uremic patients undergoing dialysis who require essential amino acid supplementation,Nutritional support in patients with renal insufficiency or failure where nonessential nitrogen sources are contraindicated
Intravenous infusion. Typical adult dose: 1.5–2.0 L/day of CLINIMIX E 5/15 (providing 75–100 g amino acids and 225–300 g dextrose per day) administered via central line; rate determined by glucose tolerance and fluid status.
Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.
Components have variable half-lives: amino acids ~0.5-1 h; dextrose ~2-4 h; electrolytes depend on renal function. Terminal half-life not applicable as a mixture.
Approximately 2-4 hours for most essential amino acids; clinical context: rapid clearance necessitates continuous infusion for stable plasma levels.
Amino acids are metabolized in the liver via transamination, deamination, and the urea cycle. Dextrose is metabolized via glycolysis and the citric acid cycle. Electrolytes (including calcium) are not metabolized but are distributed and excreted renally.
Amino acids are metabolized via transamination, deamination, and incorporation into proteins. Hepatic and renal pathways involved in nitrogen disposal and urea cycle.
Renal excretion of amino acids and electrolytes; dextrose is metabolized to CO2 and water, with minimal renal excretion. Biliary/fecal elimination is negligible (<2%).
Renal: >95% as amino acids and metabolites; negligible biliary/fecal.
Amino acids: Negligible protein binding (<5%). Dextrose: Not bound. Electrolytes: Variable (calcium ~40% bound to albumin; others minimal).
Minimal (<10%) for most amino acids; not significantly protein-bound.
Total parenteral nutrition components distribute throughout extracellular fluid; Vd ~0.2-0.3 L/kg for electrolytes and amino acids, reflecting ECF volume.
Approximately 0.2-0.4 L/kg total body water; reflects distribution primarily into extracellular fluid.
Intravenous: 100% bioavailability. Not administered by other routes.
Intravenous: 100%.
Contraindicated in severe renal impairment (GFR <25 m L/min) unless on renal replacement therapy; for GFR 25–50 m L/min, reduce dose by 25–50% and monitor electrolytes; GFR >50 m L/min: no adjustment needed.
For GFR < 30 m L/min: reduce dose to 0.5-0.8 g/kg/day; for GFR < 15 m L/min: 0.3-0.5 g/kg/day; avoid if severe untreated uremia.
Child-Pugh Class A: no adjustment; Class B: reduce nitrogen load by 30–50%; Class C: avoid or use with extreme caution (risk of hyperammonemia).
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: contraindicated due to risk of hepatic encephalopathy.
Individualized based on weight and metabolic needs. Typical: 1–2 g amino acids/kg/day and 10–15 mg/kg/min dextrose; infusion rate titrated to glucose tolerance; for neonates, start at 0.5 g amino acids/kg/day and increase gradually.
Infants and children: 1-2 g/kg/day as continuous infusion; neonates: 0.5-1 g/kg/day, titrated to metabolic response.
Use with caution due to higher risk of fluid overload and glucose intolerance; monitor renal function and serum electrolytes; start at lower end of dosing range (e.g., 1 L/day) and adjust based on tolerance.
Start at 0.6-0.8 g/kg/day; monitor renal function and protein tolerance; adjust for comorbidities like renal impairment or heart failure.
NOT FOR USE IN INFANTS OR NEONATES who are at risk of aluminum toxicity. Premature infants are particularly at risk because of immature renal function. This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration in patients with renal impairment.
Not for intravenous infusion. For oral or enteral use only. Do not administer parenterally.
Risk of hyperglycemia requiring monitoring of blood glucose and insulin administration,Risk of electrolyte imbalances including hypercalcemia, hyperkalemia, and hyperphosphatemia,Risk of aluminum toxicity, especially in neonates and patients with renal impairment,Risk of infection from catheter-related bloodstream infections,Risk of fluid overload, particularly in patients with renal or cardiac insufficiency,Monitoring of liver function tests, serum electrolytes, blood glucose, and osmolality required
Monitor serum electrolytes, BUN, and ammonia levels; risk of hyperammonemia in hepatic impairment,Use with caution in patients with metabolic acidosis or fluid overload,May cause gastrointestinal intolerance; adjust rate of administration
Hypersensitivity to any component,Patients with severe hyperglycemia or insulin resistance not adequately controlled,Patients with hypercalcemia,Patients with abnormal glucose tolerance (e.g., diabetic ketoacidosis),Infants and neonates (due to aluminum risk),Patients with galactosemia or fructose intolerance (if contains sorbitol or fructose; CLINIMIX E contains dextrose only, but caution with glucose intolerance),Severe electrolyte imbalances (e.g., hyperkalemia, hyperphosphatemia)
Hypersensitivity to any component,Phenylketonuria (contains phenylalanine),Severe hepatic failure with hyperammonemia
Enteral nutrition is not administered concurrently; TPN replaces oral intake. No specific food interactions, but oral intake should be discussed with the healthcare team if transitioning to enteral feeding.
No specific food interactions. Patients should follow prescribed dietary protein restrictions if indicated (e.g., in hepatic encephalopathy). Avoid alcohol as it may worsen liver function.
Parenteral nutrition components are generally considered essential for maternal and fetal health when oral/enteral nutrition is inadequate. No teratogenic risks have been identified at recommended doses; however, each component (amino acids, dextrose, electrolytes, vitamins) must be individually assessed. First trimester: No known structural anomalies; used as needed. Second and third trimesters: No specific fetal risks; monitor for maternal metabolic disturbances (hyperglycemia, electrolyte imbalances) which can affect fetal growth.
Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status directly impacts fetal outcomes.
Sodium: M/P ratio ~0.46. Amino acids, dextrose, electrolytes are normal constituents of breast milk and are not contraindicated. Intravenous administration does not warrant interruption of breastfeeding. Use with caution in mothers with metabolic disorders. No specific M/P ratio available for the combination product.
No data available on milk concentrations. Essential amino acids are normal components of breast milk. Use with caution; benefits likely outweigh risks in malnourished mothers.
Pregnancy increases fluid volume and metabolic demands; dose adjustments may be needed. Glucose infusion should be adjusted to maintain normoglycemia. Electrolyte requirements may increase, especially calcium (300-600 mg/day additional) and magnesium. Close monitoring of serum levels is recommended; no fixed dose adjustment schedule. Start with lower rates and titrate based on clinical response and labs.
Pregnancy increases plasma volume and glomerular filtration rate, potentially altering pharmacokinetics. Monitor clinical response and consider dose adjustments based on metabolic demands; no specific dose adjustment guidelines available.
This is a total parenteral nutrition (TPN) formulation containing 15% dextrose, 5% amino acids, electrolytes, and calcium. Use strict aseptic technique for preparation and administration. Monitor serum glucose, electrolytes, renal and hepatic function regularly. Do not add other medications unless compatibility is verified. Inspect for precipitation, especially with calcium and phosphate. Adjust infusion rate gradually to avoid hyperglycemia and rebound hypoglycemia.
Monitor serum ammonia levels in patients with hepatic impairment as essential amino acids may exacerbate hyperammonemia. Use with caution in fluid-restricted patients due to high volume load. Ensure adequate non-protein calories to promote protein synthesis and prevent amino acid catabolism. Do not administer simultaneously with blood products via same IV line.
This nutrition solution is given intravenously to provide complete nutrition when you cannot eat or drink.,Report any signs of infection at the IV site (redness, swelling, pain) or fever, chills, or shortness of breath.,Your blood sugar, electrolytes, and other lab values will be checked frequently.,Do not adjust the infusion rate yourself; it is controlled by the healthcare team.,Inform your healthcare provider if you have diabetes, kidney problems, or any allergies.
This solution provides essential amino acids to support protein synthesis when you cannot eat enough protein.,It is given intravenously; report any burning, pain, or swelling at the IV site.,Your blood may be monitored for ammonia and electrolyte levels during treatment.,Inform your healthcare provider if you have liver disease, diabetes, or fluid restrictions.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER vs AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE, answered by our medical review team.
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by CLINIMIX E 5/15 is a parenteral nutrition solution that provides essential amino acids, electrolytes, and dextrose for intravenous use. Amino acids serve as building blocks for protein synthesis, dextrose provides calories for energy metabolism, and electrolytes maintain fluid and electrolyte balance. Calcium is essential for bone mineralization, neuromuscular function, and enzyme activation.. AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is a Parenteral Nutrition Solution that works by Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER and AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER is: Intravenous infusion. Typical adult dose: 1.5–2.0 L/day of CLINIMIX E 5/15 (providing 75–100 g amino acids and 225–300 g dextrose per day) administered via central line; rate determined by glucose tolerance and fluid status.. The standard adult dose of AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is: Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER and AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER is classified as Category C. Parenteral nutrition components are generally considered essential for maternal and fetal health when oral/enteral nutrition is inadequate. No teratogenic risks have been identifie. AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is classified as Category C. Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status dire. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.